Importer & Manufacturer | Source: NPPA
Published On: 12-09-2025
Enforcement Date: 22 September, 2025
Implementation of revision in Maximum Retail Price (MRP) due to reduction in Goods and Service Tax (GST) Rates.
NPPA has issued an Office Memorandum directing all drug and medical device manufacturers/marketers to revise MRPs from 22 September 2025 to pass on the GST rate reduction recommended by the 56th GST Council. Companies must issue revised/supplementary price lists (Form V/VI) and sensitize dealers and consumers. Re‑labelling/re‑stickering of pre‑22 Sept stock is not mandatory if retail‑level compliance is ensured.
On 12 September 2025, NPPA instructed manufacturers and marketing companies of drugs/formulations (including medical devices) to revise MRPs effective 22 September 2025 in line with GST rate reductions recommended by the 56th GST Council.
Companies must issue revised or supplementary price lists (Form V/VI) to dealers, retailers, State Drug Controllers, and the Government, and proactively sensitize the supply chain and consumers using electronic, print and social media.
NPPA clarified that recall/re‑labelling/re‑stickering is not mandatory for stock released before 22 September 2025 if price compliance at the retailer level is ensured; firms opting to re‑label may do so in a phased manner to avoid shortages.
The circular also references CDSCO directions under Rule 104A (11‑09‑2025) for re‑labelling/stickering where desired.
Applicable For: Importer & Manufacturer
Reference Number: F. No 12(24)/2021/DP/NPPA/Div.II(Vol.II)-Part(1)
Notification Link